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SObjectives: The estimation of risk-adjusted in-hospital mortality is essential to allow each thoracic surgery team
to be compared with national benchmarks. The objective of this study is to develop and validate a risk model of
mortality after pulmonary resection.
Methods: A total of 18,049 lung resections for non–small cell lung cancer were entered into the French national
database Epithor. The primary outcome was in-hospital mortality. Two independent analyses were performed
with comorbidity variables. The first analysis included variables as independent predictive binary comorbidities
(model 1). The second analysis included the number of comorbidities per patient (model 2).
Results: In model 1 predictors for mortality were age, sex, American Society of Anesthesiologists score, perfor-
mance status, forced expiratory volume (as a percentage), body mass index (in kilograms per meter squared), side,
type of lung resection,extended resection, stage, chronic bronchitis, cardiac arrhythmia, coronary artery disease,
congestive heart failure, alcoholism, history of malignant disease, and prior thoracic surgery. In model 2 predic-
tors were age, sex, American Society of Anesthesiologists score, performance status, forced expiratory volume,
body mass index, side, type of lung resection, extended resection, stage, and number of comorbidities per patient.
Models 1 and 2 were well calibrated, with a slope correction factor of 0.96 and of 0.972, respectively. The area
under the receiver operating characteristic curve was 0.784 (95% confidence interval, 0.76–0.8) in model 1 and
0.78 (95% confidence interval, 0.76–0.797) in model 2.
Conclusions: Our preference is for the well-calibrated model 2 because it is easier to use in practice to estimate
the adjusted postoperative mortality of lung resections for cancer. (J Thorac Cardiovasc Surg 2011;141:449-58)Lung resection is still the main curative treatment for patients
with non–small cell lung cancer. The surgical lung most often
concerns fragile patients with chronic obstructive pulmonary
disease or other medical conditions, such as cardiovascular
disease. The risk of the operation is higher in patients with
concomitant respiratory or cardiac disease.1 Several single-
institution retrospective studies that examined the character-
istics of patients with an increased risk of mortality after major
pulmonary resection have been published.1,2 Series that span
several decades are of limited size, single-institution studies
are not sufficiently reliable, and the results reported cannot
be extrapolated to the practices of other surgical teams.3,4
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Several scoring systems based on various comorbid
conditions have previously been used to stratify patients
according to the risk of complications.1,5-7 However, these
scoring systems were developed in other populations and
thus might not be ideal for patients who undergo surgical
intervention for non–small cell lung cancer.1,5,6 In addition,
these models do not include several other prognostic
factors, such as sex, age, extent of resection, and tumor
stage, which could be relevant in these patients.
Substantial variations in postoperative mortality have
been reported by other countries and institutions, but direct
comparison is hampered by differences in definitions and se-
lection criteria. Case series from large clinics tend to show
lower mortality than do population-based studies. This could
be explained by the superior performance of specialized
institutions but might also be caused by selection bias.8 A
predictive model should be developed and validated from
a nationally representative thoracic surgery database. Epi-
thor is a national database developed by the French Society
of Thoracic and Cardiovascular Surgery.9
The objective of this study is to develop and validate a risk
model for in-hospital mortality of surgical patients with
non–small cell lung cancer. This model will be used to
stratify the aggregate population risk for risk-adjustedrdiovascular Surgery c Volume 141, Number 2 449
Abbreviations and Acronyms
ASA ¼ American Society of Anesthesiologists
AUC ¼ area under the curve
BMI ¼ body mass index
CI ¼ confidence interval
DLCO ¼ diffusion capacity for carbon monoxide
FEV ¼ forced expiratory volume
ROC ¼ receiver operating characteristic
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Scomparison of performance between units. We evaluated the
effect of individual comorbidities and the number of comor-
bidities per patient, as well as the effect of the characteristics
of patients, procedures, and tumor stage on mortality in pul-
monary resection.MATERIALS AND METHODS
Epithor: The French National Database
The French Society of Thoracic and Cardiovascular Surgery database was
established in 2003 as a voluntary initiative of general thoracic surgeons. To-
day, 70 private and public institutions record their data in the database. De-
tails of the Epithor data collection instrument can be found on the French
Society of Thoracic and Cardiovascular Surgery Web site.9 Thoracic surgery
units that applied to contribute to this database were visited and validated by
the coordinator and were then sent a confidential code. Each medical record
contains 50 variables, of which 14 are required to initialize and 2 to close the
file. Data are sent by Internet to the national database, and patients are anon-
ymous. Multiple coherence tests are then carried out to warn the participating
site of the presence of an anomaly. Each surgeon can check the quality of the
data by comparing them with national data through a quality score ranging
from 0% to 100%. Variables are collected on a data form that includes in-
formation about every patient’s personal characteristics, medical history, sur-
gical procedures, cancer staging, and outcomes.
Patient Population
Between January 2003 and December 2008, a total of 83,000 operations
were entered into the Epithor database by 81 surgical sites, including 19,031
procedures for non–small cell lung cancer. We excluded exploratory thora-
cotomy (n ¼ 982) during the study period. The final study population con-
sisted of 18,049 pulmonary resections. Baseline demographics included age,
sex, American Society of Anesthesiologists (ASA) score, performance sta-
tus (Appendix 1), body mass index (BMI; in kilograms per meter squared),
and forced expiratory volume (FEV; as a percentage). The diffusion capacity
for carbon monoxide (DLCO) and dyspnea score were excluded because too
many data were missing. In the preoperative period, the DLCO was not rou-
tinely used by thoracic surgeons. The comorbidities selected for analysis
were smoking, chronic bronchitis, coronary artery disease, cardiac arrhyth-
mia, congestive heart failure, peripheral vascular disease, pulmonary artery
hypertension, alcoholism, cirrhosis, cerebral vascular event, diabetes melli-
tus, renal insufficiency, coagulopathy, history of malignant disease, prior
thoracic surgery, preoperative chemotherapy, steroids, valvular heart dis-
ease, and pulmonary embolism. The different comorbidities are defined in
Appendix 2. Very few patients were treated with preoperative radiotherapy.
The type of procedure included limited resection (wedge resection or seg-
mentectomy) lobectomy or bilobectomy and pneumonectomy. Extended re-
section was defined as en bloc chest wall resection, a portion of the left
atrium, carinal resection, the diaphragm, and the superior vena cava. Medi-
astinal lymph node dissection included nodal sampling or radical lymphade-450 The Journal of Thoracic and Cardiovascular Surgnectomy. Surgical resection margins were classified as complete (R0) or
microscopically (R1) or macroscopically (R2) invaded. Primary lung cancer
was classified as stage I (IA or IB), II (IIA or IIB), III (IIIA or IIIB), or IV in
accordance with the American Joint Committee on Cancer.10
Outcome Definition
In-hospital mortality included patients who died within the first 30 days
after the operation and those who died later during the same hospitalization.
Missing Data
Baseline demographics (including age and sex), comorbidities, and pro-
cedure and outcome date were recorded in every case. Data concerning the
ASA score, performance status, FEV, pathological stage, and surgical resec-
tion margin status were sometimes incomplete; the proportion of missing
data varied between 1.8% and 23.6%. We assumed that the missing data
were missing at random; that is to say, the fact that the data were missing
was not related to the true (unobserved) values of the missing data.11 We
applied a multiple imputation framework to compensate for missing prog-
nostic factor data. For categorical variables (ASA score, performance status,
pathological stage, and surgical resection margin status), we applied a mul-
tinomial logistic model, and for continuous variables (FEV), we used linear
regression. Missing values for ASA scores and performance status were en-
tered by using a multinomial logistic regression model that included sex,
age, FEV, procedure, extended resection, and comorbidities. Missing values
for FEV were entered by using linear regression that included sex, age, ASA
score, performance status, procedures, side, extended resection, and comor-
bidities. Missing values for surgical pathological stage and surgical resec-
tion margin were entered by using multinomial logistic regression that
included sex, age, procedures, side, extended resection, ASA score, and
performance status.11
Development of the Risk Model
To determine independent factors for in-hospital death, we first per-
formed univariate analysis with c2 tests for binary and categorical variables
and a t test for continuous variables. Variables with a level of significance of
less than or equal to .1 in the univariate analysis were included in the mul-
tivariate analysis by means of logistic regression.12 Continuous or ranked
variables were tested to ensure conformity with the linear gradient by using
the likelihood ratio c2 statistic.12 Interaction effects were sought for all vari-
ables included in the model. All models were constructed by using back-
ward stepwise variable selection. A step-down variable selection using
Akaike’s information criterion was used as a stopping rule.12 For the pur-
pose of the regression analysis, age and FEV were continuous variables,
and the ASA score, performance status, and BMI were ranked variables.
The type of pulmonary resection, pathological stage, and surgical resection
margin status were transformed into dummy variables. The other variables
were binary: sex, side, and extended resection. Two independent analyses
were performed with comorbidity variables. The first regression analysis in-
cluded variables as independent predictive binary comorbidities by using
a step-down procedure (model 1). The second regression analysis included
the number of comorbidities per patient as a ranked variable grouped into
4 values (0, 1, 2, and 3; model 2).
Validation
The area under the receiver operating characteristic (ROC) curve, the
Somer’s Dxy correlation, and the R2 value were used to measure the
discriminatory ability of the model.12,13 The reliability of the model was
estimated by the relationship between the predicted probability and the
observed outcome in that sample. Calibration by plotting predicted
against observed probability can estimate intercepts and slopes of curves
to quantify overfitting.13 Well-calibrated models have a slope of 1, whereas
models that provide overly extreme predictions have a slope of less than 1:
low predicted probabilities are too low, and high predicted probabilities areery c February 2011
Bernard et al General Thoracic Surgerytoo high. The reliability of the model was assessed with the Hosmer–Leme-
show goodness-of-fit test.14
The internal validation of the model was assessed with bootstrap resam-
pling techniques.13 Bootstrap samples consisted of n patients randomly
drawn with replacement from the original dataset (training set) of size n.
A model in the bootstrap sample (test set) is derived and applied to the
original sample without change. The discriminatory and reliability index
from the bootstrap sample minus the index computed on the original sam-
ple is an estimate of optimism. This process is repeated for 200 bootstrap
replications to obtain an average optimism, which is subtracted from
the final model (index-corrected) fit’s apparent accuracy to obtain the
overfitting-corrected estimate.13 Calibration accuracy is estimated by using
a nonparametric smoother that relates predicted probabilities to observed
binary outcomes. After averaging many replications, the predicted
value–specific differences are then subtracted from the apparent differ-
ences, and an adjusted calibration curve is obtained.13 The mean absolute
calibration error was also estimated.13 The logistic regression models were
compared by using the measure of discriminatory ability and the reliability
index.
Discrete variables were expressed as numbers with percentages, and con-
tinuous variables were expressed as means and standard deviations. Calcu-
lations were performed with STATA 11 statistical software (StataCorp,
College Station, Tex) and R statistical software, for which we used Harrell’s
Design library (http://www.r-project.org).G
T
SRESULTS
There were 690 deaths (in-hospital mortality, 3.8%; 95%
confidence interval [CI], 3.5%–4.1%). The baseline pa-
tients’ characteristics and in-hospital mortalities for the dif-
ferent variables are shown in Table 1. The type of pulmonary
resection was the strongest significant predictor of in-
hospital mortality: 2.4% for limited resection, 3% for lobec-
tomy, and 7.7% for pneumonectomy (P<.00001, Table 1).
Extended resection was associated with a 7% risk of in-
hospital mortality (P< .0001, Table 1). Mortality was 3%
in patients with left-sided pulmonary resection and 4.4%
in those with right-sided pulmonary resection (P< .0001,
Table 1). Comorbidity variables associated with increased
mortality in univariate analyses included chronic bronchitis,
coronary artery disease, cardiac arrhythmia, congestive heart
failure, peripheral vascular disease, alcoholism, renal insuf-
ficiency, coagulopathy, history of malignant disease, and
prior thoracic surgery (Table 1).Risk Models for In-Hospital Mortality
In model 1 multivariate analysis identified age, sex, ASA
score, performance status, FEV, BMI, side, lobectomy,
pneumonectomy, extended resection, stage III disease, stage
IV disease, chronic bronchitis, cardiac arrhythmia, coronary
artery disease, congestive heart failure, alcoholism, history
of malignancy disease, and prior thoracic surgery as inde-
pendent predictors of in-hospital mortality (Appendix 3).
In model 2 multivariate analysis identified age, sex, ASA
score, performance status, FEV, BMI, side, lobectomy,
pneumonectomy, extended resection, stage III disease, stage
IV disease, and number of comorbidities per patient as inde-
pendent predictors of in-hospital mortality (Table 2). TheThe Journal of Thoracic and Carelationship of FEV was linear with respect to the logit of
risk (P ¼ .23) without a scale or spline transformation.
The linear gradient of the variables age (P ¼ .6), ASA score
(P ¼ .53), and performance status (P ¼ .37) was accepted.
The test for the linear gradient of the variables BMI
(P ¼ .007) and number of comorbidities per patient
(P ¼ .027) was rejected. Therefore these 2 variables were
transformed into dummy variables (Table 2). Three interac-
tions were identified between side and pneumonectomy,
FEV and pneumonectomy, and FEV and extended resection
(Table 2). The predicted logit at a certain value of FEV dif-
fered according to the type of pulmonary resection. In pa-
tients who had undergone pneumonectomy, the predicted
logit varied little according to the value of FEV. This was
not the case for patients who had undergone limited resection
or lobectomy (Figure 1). The predicted logit varied little ac-
cording to the value of FEV in patients who had undergone
extended resection, whereas it decreased linearly among
patients who had undergone simple pulmonary resection
(Figure 2). Patients who had undergone right-sided pneumo-
nectomy had an adjusted odds ratio of 2.9 (95% CI, 1.44–
5.88), and patients with left-sided pneumonectomy had an
adjusted odds ratio of 1.78 (95% CI, 0.87–3.645; Figure 3).
Validation
The performance of the prediction model for the training
set and its ability to predict in-hospital mortality for the test
set were compared (Table 3). The index-corrected Dxy cor-
relation and R2 values for models 1 and 2 were comparable
(Table 3). The calibration plots are shown in Figure 4.The
slope-correction factor for models 1 and 2 was 0.96 and
0.972, respectively (Table 3). The Hosmer–Lemeshow
goodness-of-fit statistic was not statistically significant in
models 1 and 2 (Table 3).
Comparison of the 2 Models
Areas under the ROC curves compared the discriminatory
abilities of models 1 and 2. The area under the curve (AUC)
for model 1 was 0.784 (95% CI, 0.76–0.8), whereas it was
0.78 (95% CI, 0.76–0.797) in model 2; the AUCs were not
significantly different (P ¼ .19). With bootstrapping, the
AUC for model 1 was unchanged at 0.785 (95% CI, 0.77–
0.8) and for model 2, it was unchanged at 0.78 (95% CI,
0.765–0.8). The reliability index and calibration were
slightly better in model 2 than in model 1 (Table 3 and
Figure 4). According to the bootstrap calibration curve using
a nonparametric smoother to relate predicted probabilities to
observed binary outcomes, the mean absolute error was
0.002 for model 1 and 0.0014 for model 2.
DISCUSSION
Both model 1, which included individual comorbidities,
and model 2, which took into account the number of comor-
bidities per patient, had good discrimination, as shown byrdiovascular Surgery c Volume 141, Number 2 451
TABLE 1. Categorical risk factors in patient survival and in-hospital mortality
Variables Categories Survivors (n ¼ 17,359) In-hospital mortality (n ¼ 690) P value
Sex Male 13,185 (95.5%) 618 (4.5%) .00001
Female 4174 (98.3%) 72 (1.7%)
Age Years 62.5  10 66.9  9.3 .00001
ASA score 1 3114 (98.7%) 42 (1.3%) .00001
2 9351 (97%) 297 (3%)
3 4735 (94%) 321 (6%)
4 159 (84%) 30 (16%)
Forced expiratory volume % 72.6  18.8 66.5  17.8 .00001
Performance status 0 7375 (98%) 158 (2%) .00001
1 8233 (95.6%) 377 (4.4%)
2 1538 (93%) 120 (7%)
3 213 (86%) 35 (14%)
Body mass index 17 kg/m2 356 (90.4%) 38 (9.6%) .0001
18–21 kg/m2 3206 (95.7%) 143 (4.3%)
22–26 kg/m2 8126 (96%) 330 (4%)
>26 kg/m2 5671 (97%) 179 (3%)
Smoking No 11,940 (96%) 506 (4%) .01
Yes 5419 (97%) 184 (3%)
Chronic bronchitis No 14,471 (96%) 549 (4%) .009
Yes 2888 (95%) 141 (5%)
Coronary artery disease No 16,158 (96.4%) 606 (3.6%) .00001
Yes 1201 (93.5%) 84 (6.5%)
Cardiac arrhythmia No 16,732 (96.3%) 646 (3.7%) .00001
yes 627 (93.4%) 44 (6.6%)
Congestive heart failure No 16,836 (96.3%) 640 (3.7%) .0001
Yes 523 (91.3%) 50 (8.7%)
Peripheral vascular disease No 15,583 (96.5%) 562 (3.5%) .00001
Yes 1776 (93.3%) 128 (6.7%)
Pulmonary artery hypertension No 17,314 (96%) 687 (4%) .38
Yes 45 (93.75%) 3 (6.25%)
Alcoholism No 16,416 (96.3%) 633 (3.7%) .001
Yes 943 (94.3%) 57 (5.7%)
Cirrhosis No 17,232 (96.2%) 682 (3.8%) .2
Yes 127 (94%) 8 (6%)
Cerebral vascular events No 16,814 (96%) 661 (4%) .12
Yes 545 (95%) 29 (5%)
Diabetes mellitus No 16,000 (96%) 626 (4%) .16
Yes 1359 (95.5%) 64 (4.5%)
Renal insufficiency No 17,192 (96%) 677 (4%) .017
Yes 167 (93%) 13 (7%)
Coagulopathy No 16,211 (96.3%) 627 (3.7%) .01
Yes 1148 (95%) 63 (5%)
History of malignant disease No 14,696 (96.4%) 554 (3.6%) .002
Yes 2663 (95%) 136 (5%)
Prior thoracic surgery No 16,442 (96.4%) 617 (3.6%) .0001
Yes 917 (92.6%) 73 (7.4%)
Preoperative chemotherapy No 16,095 (96.2%) 629 (3.8%) .12
Yes 1264 (95.4%) 61 (4.6%)
Steroids No 17,311 (96.2%) 688 (3.8%) .9
Yes 48 (96%) 2 (4%)
Pulmonary embolism No 17,196 (96.2%) 683 (3.8%) .84
Yes 163 (96%) 7 (4%)
Valvular heart disease No 17,299 (96.2%) 687 (3.8%) .7
Yes 60 (95%) 3 (4%)
(Continued)
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TABLE 1. Continued
Variables Categories Survivors (n ¼ 17,359) In-hospital mortality (n ¼ 690) P value
Pulmonary resection Limited resection 1778 (97.6%) 43 (2.4%) .00001
Lobectomy 12,746 (97%) 409 (3%)
pneumonectomy 2835 (92.3%) 238 (7.7%)
Side Right 9753 (95.6%) 448 (4.4%) .0001
Left 7606 (97%) 242 (3%)
Extended resection No 15,805 (96.5%) 574 (3.5%) .0001
Yes 1554 (93%) 116 (7%)
Mediastinal lymph node dissection No 782 (97%) 24 (3%) .34
Sampling 1385 (96.5%) 50 (3.5%)
Lymphadenectomy 14,352 (96%) 580 (4%)
Pathological stage IA or IB 8613 (97.25%) 244 (2.75%) .0001
IIA or IIB 3051 (96%) 113 (4%)
IIIA or IIIB 4503 (94%) 265 (6%)
IV 1192 (96%) 48 (4%)
Surgical resection margin status R0 16,760 (96%) 652 (4%) .006
R1 457 (94.6%) 26 (5.4%)
R2 142 (92%) 12 (8%)
No. of comorbidities per patient None 6418 (98%) 123 (2%) .00001
1 5902 (96%) 231 (4%)
2 3884 (94%) 242 (6%)
3–4 1155 (92.5%) 94 (7.5%)
Bernard et al General Thoracic Surgery
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correlation, and R2. Model 2, by taking into account the
number of comorbidities per patient, considers that each of
the comorbidities carries the same weight in the predictionTABLE 2. Logistic regression models including the number of comorbidit
Variables Categories
Sex Female vs male
Age Increasing years
Side Left vs right
ASA score Increasing units
Performance status Increasing units
Body mass index 17 kg/m2
18–21 kg/m2
22–26 kg/m2
>26 kg/m2
FEV Increasing%
Lobectomy Yes vs no
Pneumonectomy Yes vs no
Pneumonectomy $ FEV Interaction
Side $ pneumonectomy Interaction
Extended resection Yes vs no
Extended resection $ FEV Interaction
Stage III vs (I or II or IV)
Stage IV vs (I or II or III)
No. of comorbidities
per patient
0
1
2
3 or 4
Intercept
CI, Confidence interval; ASA, American Society of Anesthesiologists; FEV, forced expirat
The Journal of Thoracic and Caof postoperative mortality, as demonstrated by Falcoz and
colleagues.15 However, their study was very different from
ours because it involved procedures on the lung, mediasti-
num, and pleura for benign and malignant diseases.ies per patient (model 2) for prediction of in-hospital mortality
Model 2
Coefficients 95% CI P value
0.745 1 to 0.49 .0001
0.045 0.037 to 0.05 .0001
0.42 0.62 to 0.21 .0001
0.39 0.25 to 0.53 .0001
0.3 0.17 to 0.41 .0001
Ref
0.89 1.3 to 0.5 .0001
1.18 1.56 to 0.8 .0001
1.53 1.9 to 1.13 .0001
0.01 0.016 to 0.005 .0001
0.56 0.23 to 0.89 .001
1.09 0.39 to 1.8 .002
0.01 0.0004 to 0.02 .04
0.485 0.83 to 0.14 .006
0.9 1.74 to 0.06 .035
0.018 0.006 to 0.029 .003
0.47 0.29 to 0.64 .0001
0.5 0.18 to 0.82 .002
Reference
0.5 0.27 to 0.73 .0001
0.81 0.58 to 1 .0001
0.95 0.66 to 1.25 .0001
6.64 7.53 to 5.74
ory volume.
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FIGURE 1. Interaction of pneumonectomy and forced expiratory volume
(FEV; as a percentage). CI, Confidence interval.
FIGURE 2. Interaction of extended resection and forced expiratory vol-
ume (FEV; as a percentage). CI, Confidence interval.
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calibration with a slope of 0.972 compared with model 1.
The better validation of model 2 can be explained by the
fact that parsimony is more important than accuracy.13
Our preference is for model 2 because it is easier to use in
practice to estimate adjusted postoperative mortality in
lung resections for cancer. Among the methods for internal
validation, the bootstrap method used in our study is the
most efficient for estimations of internal validity in a predic-
tive logistic regression model.16 Ideally, this model should
have been validated on an external validation dataset, but
this would have been difficult because the patients are in-
cluded in a national database, making it virtually impossible
to find an independent validation dataset.
The values for the area under the ROC curve of the 2
models were estimated at around 0.78, indicating reasonable
discriminatory ability. The DLCO, which is regarded as
a prognostic variable,17 could not be included in our model
because this variable was not routinely used in French prac-
tice. In the multivariate model of laboratory values, Harpole
and associates18 included variables such as serum albumin
and red blood cell count, which were not included in the Ep-
ithor database. However, the predictive values of the model
of Harpole and associates are no better than the area under
the ROC curve in our study. Indeed, the c-indexes for
Harpole and associates’ mortality models ranged from
0.749 to 0.729. Other authors18,19 used intraoperative
variables, such as operative time and blood transfusions.
In these 2 studies the prediction models using these
variables showed no significant superiority. Authors used
individual comorbidities or the Charlson comorbidity
index.20-22 Strand and coworkers,23 in their study based on
a Swedish cancer registry, identified the Charlson comorbid-
ity index as a prognostic factor with minimal effect on
postoperative mortality. Other studies that validated the
Charlson comorbidity index involved small samples.20
Overall, our approach using the number of comorbidities454 The Journal of Thoracic and Cardiovascular Surgper patient is easy to use and does not penalize the predictive
model for in-hospital mortality.
The challenge for a national database is to find the right
compromise between ease of use on a daily basis by includ-
ing information with little variation and loss of precision.
The possible lack of precision of these models could be ex-
plained by missing data, even though we tried to correct for
this problem by using a multiple imputation method. This
method assumes that missing values are independent of
the occurrence of postoperative death. The estimation of
missing values increases the power of the multivariate anal-
ysis, but it is possible that one cannot compensate for the
lack of information. In the future, to reduce the amount of
missing data, quality control audits will be implemented.
The few studies of multivariate models for the prediction of
postoperative mortality in thoracic surgery did not take into
account interactions with a clinical interest.17,18,21 The
adjusted level of risk of death for pneumonectomy was
different depending on which lung was involved: patients
with right-sided pneumonectomy were 3 times more likely
to die in the hospital than were patients undergoing limited re-
section or lobectomy. Patients with left-sided pneumonec-
tomy had an odds ratio of 1.78. Other interactions were
taken into account in our models; these were extended resec-
tion with FEV and pneumonectomy with FEV. The risk of
death in patients with extended resection or pneumonectomy
was independent of FEV values. This was not the case for pa-
tients with simple resection or lobectomy or limited resection,
in whom the risk of death correlated linearly with FEV values.
The introduction of interaction terms in a multivariate model
increases the number of parameters but probably improves its
discriminative ability. Finally, because this model to estimate
risk-adjusted mortality will be used in routine clinical practice,
the use of variables, such as pathological stage, is justified.
The strength of this risk model is the size and quality of the
dataset, which includes patients undergoing operations in
France performed by private or public surgical teams. Asery c February 2011
FIGURE 3. Interaction of side and type of lung resection.
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resentative of practices in thoracic surgery in France. How-
ever, this report does have several limitations. As with all
noncompulsory databases, there is a potential for incomplete
submissions and for centers with poor outcomes to abstain
from participating. The national Epithor database will develop
a data verification system to reduce the amount of nonsensical
and missing data by using an on-site audit procedure. Another
indirect proof of the reliability of this database is that death
rates in different types of lung resection are entirely consistent
with the literature, especially in large databases.22 Other pre-
dictive models developed from cancer registries or large data-
bases18,22–26 are comparable with our model.
Databases such as Epithor are the best tools to develop
a predictive model that is easy to use by thoracic surgeons
to estimate adjusted in-hospital mortality. However, the de-
velopment of this type of database is an additional constraint
for surgeons. Ultimately, it is difficult to create national data-
bases, such as Epithor, with all the limitations described
above. The advantage of this model lies in the fact that the var-
iables are essentially clinical and easily collected every day.
The estimation of risk-adjusted in-hospital mortality is es-
sential in that it will allow each thoracic surgery team to be
compared with national benchmarks and will foster a processTABLE 3. Validation of 2 logistic regression models using the bootstrap m
Model 1
Training set Test set Optimism Index corre
Dxy correlation 0.576 0.56 0.0157 0.551
R2 0.158 0.147 0.01 0.141
Intercept 0 0.106 0.106 0.106
Slope 1 0.9608 0.04 0.9608
HL (c2) 9.8 9
HL (P value) .27 .5
HL, Hosmer–Lemeshow goodness-of-fit statistic.
The Journal of Thoracic and Caof improvement in the quality of surgical practices.22 A quality
program is established from the national database Epithor to al-
low each thoracic surgery center to compare their results with
the national average by using graphic methods, such as the fun-
nel plot.27 Finally, the calculation of risk-adjusted in-hospital
mortality for each thoracic surgery center will be done over
3 years to obtain enough events. In-hospital mortality is only
one indicator of quality among others that will be developed.
The software used by the Epithor database incorporates the cal-
culation of risk-adjusted mortality and graphics for quality
control of each thoracic surgery team. Moreover, the Epithor
database is a useful for the accreditation of thoracic surgeons.
In conclusion, the development of a risk model is the nec-
essary first step in the analysis of an approach to improve
clinical practice in thoracic surgery. This risk model is
easy to use with the Epithor database and is robust, as dem-
onstrated by means of validation. The use of in-hospital mor-
tality as an indicator of quality and the development of this
risk model is part of a quality assurance program piloted by
the French Society of Thoracic and Cardiovascular Surgery.
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rdiovascular Surgery c Volume 141, Number 2 455
FIGURE 4. Calibration plot of observed versus predicted mortality for models 1 and 2.
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991-7.APPENDIX 1. American Society of Anesthesiologists physical status
classification system
Score 1 A normal healthy patient
Score 2 A patient with mild systemic disease
Score 3 A patient with severe systemic disease
Score 4 A patient with severe systemic disease that is
a constant threat to life
Score 5 A moribund patient who is not expected to
survive without operation
Score 6 A declared brain-dead patient whose organs
are being removed for donor purposes
Performance status*
Score 0 Asymptomatic
Score 1 Symptomatic but completely ambulatory
Score 2 Symptomatic,<50% in bed during the day
Score 3 Symptomatic,>50% in bed but not bedbound
Score 4 Bedbound
Score 5 Death
*Performance status is the Eastern Cooperative Oncology Group score.
APPENDIX 2. Definition of comorbidities
Comorbidity
Smoking Chronic cigarette smokers included patient
smoking for>8 weeks preceding lung
Chronic Bronchitis Chronic cough present intermittently or ev
Coronary artery disease Angina or previous myocardial infarction
medical treatment
Cardiac arrhythmia Atrial flutter or atrial fibrillation or suprav
Congestive heart failure Previous symptoms of heart failure (acute
cardiomegaly on chest radiographic im
Peripheral vascular disease Peripheral artery occlusive disease treated w
Pulmonary artery hypertension A mean pulmonary artery pressure>25 m
Alcoholism More than 2 alcoholic beverages per day f
Cirrhosis Replacement of liver tissue by fibrosis, sc
Cerebral vascular events Stroke or transient ischemic attack caused
Diabetes mellitus Type 1 or type 2 diabetes
Renal insufficiency Chronic renal insufficiency treated with di
Coagulopathy Acquired or autoimmune or genetic clottin
History of malignant disease Malignancies treated within the previous 5
Prior thoracic surgery Previous ipsilateral or contralateral thorac
Steroids Long-term use of corticosteroids
Pulmonary embolism History of pulmonary embolism
Valvular heart disease Aortic valve stenosis or aortic insufficienc
or surgery*
*Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart d
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ages) managed with medical treatment (Left ventricular function>30%)
ith surgical intervention or medical treatment or abdominal aortic aneurysm
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APPENDIX 3. Logistic regression model with independent predictive binary comorbidities (model 1) for prediction of in-hospital mortality
Model 1
Variables Categories Coefficients 95% CI P value
Sex Female vs male 0.74 1 to 0.48 .0001
Age Increasing years 0.048 0.039 to 0.057 .0001
Side Left vs right 0.43 0.635 to 0.22 .0001
ASA score Increasing units 0.39 0.25 to 0.53 .0001
Performance status Increasing units 0.31 0.19 to 0.43 .0001
Body mass index 17 kg/m2 Reference
18–21 kg/m2 0.87 1.27 to 0.48 .0001
22–26 kg/m2 1.15 1.54 to 0.77 .0001
>26 kg/m2 1.46 1.86 to 1.07 .001
FEV Increasing% 0.011 0.017 to 0.005 .0001
Lobectomy Yes vs no 0.63 0.29 to 0.97 .0001
Pneumonectomy Yes vs no 1.07 0.36 to 1.78 .004
Pneumonectomy $ FEV Interaction 0.01 0.0012 to 0.02 .02
Side $ pneumonectomy Interaction 0.47 0.82 to 0.13 .008
Extended resection Yes vs no 0.92 1.76 to 0.08 .03
Extended resection $ FEV Interaction 0.018 0.006 to 0.03 .002
Stage III vs I or II or IV 0.49 0.31 to 0.66 .0001
Stage IV vs I or II or III 0.53 0.2 to 0.85 .001
Chronic bronchitis Yes vs no 0.2 0.002 to 0.4 .05
Cardiac arrhythmia Yes vs no 0.38 0.05 to 0.72 .02
Coronary artery disease Yes vs no 0.44 0.2 to 0.7 .0001
Congestive heart failure Yes vs no 0.52 0.2 to 0.84 .001
Peripheral vascular disease Yes vs no 0.39 0.18 to 0.6 .0001
Alcoholism Yes vs no 0.645 0.34 to 0.94 .0001
History of malignant disease Yes vs no 0.36 0.15 to 0.56 .001
Prior thoracic surgery Yes vs no 0.82 0.54 to 1.09 .0001
Intercept 6.7 7.6 to 5.8
CI, Confidence interval; ASA, American Society of Anesthesiologists; FEV, forced expiratory volume.
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